Why the study?
Does prestroke antiplatelet therapy improve early prognosis (handicap at discharge and mortality) in patients with first-ever stroke?
Does prestroke antiplatelet therapy improve early prognosis (handicap at discharge and mortality) in patients with first-ever stroke?
Prestroke antiplatelet therapy is associated with less severe handicap at discharge in patients with first-ever stroke, and reduced 1-month mortality specifically in cardioembolic stroke.
Answers are grounded in this paper and cite their sources.
May lessen severe handicap at discharge in first-ever stroke; hypothesis-generating and should not yet change practice.
BACKGROUND AND PURPOSE: Previous antiplatelet therapy (APT) in cardiovascular prevention is common in patients with first-ever stroke. We aimed to evaluate the prognostic value of APT on early outcome in stroke patients. METHODS: All first-ever strokes from 1985 to 2011 were identified from the population-based Stroke Registry of Dijon, France. Demographic features, risk factors, prestroke treatments and clinical information were recorded. Multivariate analyses were performed to evaluate the associations between pre-admission APT and both severe handicap at discharge, and mortality at 1 month and 1 year. RESULTS: Among the 4275 patients, 870 (20.4%) were previously treated with APT. Severe handicap at discharge was noted in 233 (26.8%) APT users and in 974 (28.7%) non-users. Prestroke APT use was associated with lower odds of severe handicap at discharge [adjusted odds ratio (OR): 0.79; 95% confidence interval (CI): 063-1.00; P = 0.046], non-significant better survival at 1 month [adjusted hazard ratio (HR): 0.87; 95% CI: 0.70-1.09; P = 0.222] and no effect on 1-year mortality (HR: 0.94; 95% CI 0.80-1.10; P = 0.429). In stratum-specific analyses, APT was associated with a lower risk of 1-month mortality in patients with cardioembolic ischaemic stroke (HR: 0.65; 95% CI: 0.43-0.98; P = 0.040). CONCLUSIONS: APT before stroke was associated with less severe handicap at discharge, with no significant protective effect for mortality at 1 month except in patients with cardioembolic stroke. No protective effect of APT was observed for mortality at 1 year. Further studies are needed to understand the mechanisms underlying the distinct effects of prior APT observed across the ischaemic stroke subtypes.
No takes yet. Share an insight, caveat, or question.
Béjot et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: